| Assessing the economic burden of type 2 diabetes in China reflecting the current standard of the disease management and for improved management scenarios using a modeling approach. |
| Author(s): Foos V1, Lamotte M1, McEwan P4, Jiang X3, Zhang YL3, Qu S2, De Moor R1, Ramos R1, Xiong T2, Wang K3 |
| Affiliations(s): 1 IMS Health, Brussels, Belgium 2 IMS Health, Shanghai, China 3 Eli Lilly, Shanghai, China 4 Swansea University, Wales |
| Publication(s): 22nd ISPOR Annual International Meeting, 2017, May 20-24, Boston, MA, USA |
| Document Type(s): Abstract |
| Countries: China |
C:
Y: |
Diabetes
2017 |
|
L:
A: |
English
Cost effectiveness |
|
 |
| |
| |
| THE ANALYSIS OF INPATIENTS COST OF BREAST CANCER IN CHINA, 2011 |
| Author(s): Song S, Wang Z, Zhang M |
| Affiliations(s): IMS consulting group, Shanghai, China |
| Publication(s): ISPOR 18th Annual European Congress
Milan, Italy
November, 2015 |
| Document Type(s): Poster |
| Countries: China |
C:
Y: |
Mental health, Oncology
2015 |
|
L:
A: |
English
|
|
|
| |
| |
| Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China |
| Author(s): Tan S1, Wang X2, Wu B3, Kang H4, Li Q5, Chen Y6, Chen C6, Hajek P7, Patel D8,
Gao X8 |
| Affiliations(s): 1IMS Health, Singapore |
| Publication(s): Value in Health, Volume 3, May 2014, Pages 94–100
|
| Document Type(s): Article |
| Countries: China |
| Click here for the abstract |
C:
Y: |
Respiratory disease
2014 |
|
L:
A: |
English
Cost effectiveness |
|
|
| |
| |
| HTA, budget impact tools and international price referencing from China’s perspective: what are the current developments and future considerations? |
| Author(s): Koh L1, Li SC2, Zhang M3, Glaetzer C1 |
| Affiliations(s): 1 Johnson & Johnson, Singapore, Singapore 2 School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia 3 IMS Consulting, Shanghai, China |
| Publication(s): ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
| Document Type(s): Panel presentation |
| Countries: China |
C:
Y: |
Pricing and reimbursement
2014 |
|
L:
A: |
English
Pricing & Reimbursement |
|
|
| |
| |
| Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. |
| Author(s): Popat S1, Mok T2, Yang JC3, Wu YL4, Lungershausen J5, Stammberger U5, Griebsch I5, Fonseca T6, Paz-Ares L7 |
| Affiliations(s): 1Royal Marsden Hospital, London, UK. 2State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong.
3National Taiwan University, Taipei, Taiwan.
4Guangdong Lung Cancer Institute, Guangzhou, China.
5Boehringer Ingelheim GmbH, Ingelheim, Germany.
6IMS Health, London, UK.
7Instituto de Biomedicina de Sevilla - IBIS (University Hospital Virgen del Rocío, US, CSIC), Seville, Spain.
|
| Publication(s): Lung Cancer. 2014 Aug;85(2):230-8 |
| Document Type(s): Article |
| Countries: China, Germany, Hong Kong, Spain, Taiwan, UK |
| Click here for the abstract |
C:
Y: |
Oncology
2014 |
|
L:
A: |
English
Meta analysis |
|
|
| |
| |
| Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. |
| Author(s): Gerlier L1, Lamotte M1, Caputo J2, Tan R3 |
| Affiliations(s): 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore |
| Publication(s): 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
| Document Type(s): Abstract, Poster |
| Countries: Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand |
C:
Y: |
Ophthalmology
2012 |
|
L:
A: |
English
Burden of illness |
|
|
| |
| |
| Direct medical costs of Diabetes Mellitus in China: Annual cost of illness and long-term projections using a validated diabetes model |
| Author(s): Palmer JL1, Caputo J2, Foos V1, Grant D3, Lamotte M4, Lloyd A3, McEwan P5 |
| Affiliations(s): 1 IMS Health, Basel, Switzerland, 2 IMS Health, Singapore, Singapore, 3 IMS Health, London, UK, 4 IMS Health Consulting Group, Vilvoorde, Belgium, 5 HEOR Consulting, Monmouth, Monmouthshire, UK |
| Publication(s): ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
| Document Type(s): Poster |
| Countries: China |
| Click here for the abstract |
C:
Y: |
Diabetes
2012 |
|
L:
A: |
English
Cost of illness |
|
|
| |
| |
| Usage of Self-Monitoring of Blood Glucose (SMBG) by Diabetes Therapy Type in Larger Cities in China. |
| Author(s): Mast O1, Tan A2, Zweyer S2, Perridy D2. |
| Affiliations(s): 1Roche, Mannheim, Germany
2Cegedim Strategic Data, Shanghai, China
|
| Publication(s): ISPOR 5TH ASIA-PACIFIC CONFERENCE , TAIPEI, TAIWAN |
| Document Type(s): Poster |
| Countries: China |
| Click here for the abstract |
C:
Y: |
Diabetes
2012 |
|
L:
A: |
English
Compliance, Retrospective database analysis |
|
|
| |
| |
| UTILIZATION OF FPG, HBA1C AND SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN COMMUNITY HEALTH CENTERS IN THE SHANGHAI AREA. |
| Author(s): Mast O1, Tan A2 |
| Affiliations(s): 1Roche, Mannheim, Germany
2Cegedim Strategic Data, Shanghai, China |
| Publication(s): ISPOR 5TH ASIA-PACIFIC CONFERENCE, TAIPEI, TAIWAN |
| Document Type(s): Poster |
| Countries: China |
| Click here for the abstract |
C:
Y: |
Diabetes
2012 |
|
L:
A: |
English
Compliance, Survey research |
|
|
| |
| |
| Real World Patient Profile of Patients with Reduced Ejection Fraction Heart Failure (HF-REF) in 5 Regions of China. |
| Author(s): Li XY, Crawford B, Liao YH, Tanaka E, Wang D, Sung J, Zheng J, McDonald J. |
| Affiliations(s): |
| Publication(s): ISPOR (June 2 – 6, 2012, Washington DC |
| Document Type(s): Poster |
| Countries: China |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease
2012 |
|
L:
A: |
English
|
|
|
| |
| |
 1 of 2 
|
